NCT06862856 - Flotufolastat F 18 PET in Men with Very Low PSA Recurrence | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

December 1, 2026

Conditions

Prostate Cancer (Adenocarcinoma)Prostate Specific Antigen

Interventions

DIAGNOSTIC_TEST

Positron Emission Tomography (PET)

This is a PET scan with flotufolastat F 18 injection.

Trial Locations (2)

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston